Landmark TrialRCTRandomized Controlled Trial
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
New England Journal of Medicine2007IF: 25.4
Andrew J. Ullmann, Jeffrey H. Lipton, David H. Vesole, Pranatharthi Chandrasekar, Amelia Langston, Stefano Tarantolo, Hildegard Greinix, Wellington Morais de Azevedo, Vijay Reddy, Navdeep Boparai, Lisa D. Pedicone, Hernando Patino, Simon Durrant
Abstract
Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD. It was superior in preventing invasive aspergillosis and reducing the rate of deaths related to fungal infections. (ClinicalTrials.gov number, NCT00034645 [ClinicalTrials.gov].).